Lisset Hermida
Overview
Explore the profile of Lisset Hermida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lobaina Y, Musacchio A, Ai P, Chen R, Suzarte E, Chinea G, et al.
Virol J
. 2024 Nov;
21(1):310.
PMID: 39609857
The Hepatitis B core antigen (HBcAg) has been used as a carrier of several heterologous protein fragments based on its capacity to form virus-like particles (VLPs) and to activate innate...
2.
Lobaina Y, Chen R, Suzarte E, Ai P, Musacchio A, Lan Y, et al.
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932317
A chimeric protein, formed by two fragments of the conserved nucleocapsid (N) and S2 proteins from SARS-CoV-2, was obtained as a recombinant construct in . The N fragment belongs to...
3.
Lobaina Y, Chen R, Suzarte E, Ai P, Huerta V, Musacchio A, et al.
Viruses
. 2024 Mar;
16(3).
PMID: 38543783
Despite the rapid development of vaccines against COVID-19, they have important limitations, such as safety issues, the scope of their efficacy, and the induction of mucosal immunity. The present study...
4.
Valdes I, Gil L, Lazo L, Cobas K, Romero Y, Bruno A, et al.
Vaccine
. 2023 Aug;
41(40):5892-5900.
PMID: 37599141
Zika virus infection continues to be a global concern for human health due to the high-risk association of the disease with neurological disorders and microcephaly in newborn. Nowadays, no vaccine...
5.
Lobaina Y, Chen R, Suzarte E, Ai P, Huerta V, Tan C, et al.
Arch Virol
. 2023 Jun;
168(7):190.
PMID: 37351679
Due to the rapid development of new variants of SARS-CoV-2 as well as the real threat of new coronavirus zoonosis events, the development of a preventive vaccine with a broader...
6.
Lobaina Y, Chen R, Ai P, Yang L, Alvarez-Lajonchere L, Suzarte E, et al.
Viral Immunol
. 2023 Feb;
36(3):222-228.
PMID: 36735580
Since the beginning of the pandemic, the pre-existing immunity against SARS-CoV-2 has been postulated as one possible cause of asymptomatic infections. Later, various works reported that pre-existing immune response against...
7.
Valdes I, Lazo L, Hermida L, Guillen G, Gil L
Front Immunol
. 2019 Sep;
10:1956.
PMID: 31507591
Dengue is one of the most important diseases transmitted by mosquitoes. Dengvaxia®, a vaccine registered in several countries, cannot be administered to non-immune individuals and children younger than 9 years...
8.
Valdes I, Izquierdo A, Cobas K, Thao P, Anh Duc H, Duc Loc H, et al.
J Gen Virol
. 2019 May;
100(6):975-984.
PMID: 31090533
The development of live-attenuated vaccines against Dengue virus (DENV) has been problematic. Dengvaxia, licensed in several countries where DENV is endemic, has shown low efficacy profiles and there are safety...
9.
Lazo L, Valdes I, Guillen G, Hermida L, Gil L
Expert Rev Vaccines
. 2019 Jan;
18(2):161-173.
PMID: 30677305
Introduction: Dengue fever remains as a health problem worldwide. Although Dengvaxia®, was registered in several countries, the results after the immunization of people suggest an increase of risk in non-immune...
10.
Martinez R, Nunez de Villavicencio-Diaz T, Sanchez A, Ramos Y, Ferro J, Gil Gonzalez L, et al.
Biochem Biophys Rep
. 2017 Sep;
5:379-387.
PMID: 28955845
Background: Growth hormone secretagogues (GHS), among other factors, regulate the release of GH. The biological activity of the secretagogue peptide A233 as a promoter of growth and innate immunity in...